IRX 2

Next Previous
Drug Profile

IRX 2

Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IRX Therapeutics
  • Developer IRX Therapeutics; Providence Health & Services; University of Southern California
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Head and neck cancer; Vulvar intraepithelial neoplasia
  • Phase I Breast cancer

Most Recent Events

  • 08 Nov 2017 Clinical trials in Cervical cancer (Early-stage disease) (Parenteral) (prior to November 2017)
  • 08 Nov 2017 Phase-II clinical trials in Cervical intraepithelial neoplasia (Combination therapy) in USA (Submucosal) , NCT03267680)
  • 08 Nov 2017 Phase-II clinical trials in Vulvar intraepithelial neoplasia (Combination therapy) in USA (SC) , NCT03267680)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top